Zydus Lifesciences Chemotherapy drug Pemetrexed gets USFDA okay
The drug will be manufactured at Zydus Hospira.
Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such...
Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) today announced that the company has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta).
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.
The drug will be manufactured at Zydus Hospira.
Read also: Zydus Lifesciences bags USFDA nod for Bortezomib for Injection to treat cancer
Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March'22). The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Aurobindo Pharma arm bags USFDA nod for Pemetrexed for Injection
Zydus group is headquartered in Ahmedabad, India, and ranks 4th in the Indian pharmaceutical industry. The group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Read also: Zydus unveils Bemdac to treat bad cholesterol in India
